Atara Biotherapeutics Q1 2025 Earnings Results & Report

Atara Biotherapeutics EPS Results

• Actual EPS: $3.50
• Consensus EPS: -$3.07
• Beat/Miss: Beat by +$6.57
• One Year Ago EPS: N/A
• EPS Beat Rate: 7 of last 8 quarters

Atara Biotherapeutics Revenue Results

• Actual Revenue: $98.10 million
• Expected Revenue: $4.30 million
• Beat/Miss: Beat by +$93.80 million
• YoY Revenue Growth: N/A

Atara Biotherapeutics (NASDAQ:ATRA) is a biotechnology company focused on developing T-cell immunotherapies for cancer and serious diseases associated with viral infections. The company’s approach uses allogeneic, or donor-derived, T cells that are selected or engineered to recognize disease-related targets, with the goal of providing off-the-shelf treatment options.

Atara’s lead product, Ebvallo (tabelecleucel), is an allogeneic T-cell immunotherapy designed to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in certain patients who have received a solid-organ or hematopoietic-cell transplant. Ebvallo received marketing authorization in the European Union and is commercialized in international markets through collaboration arrangements. The company has also developed investigational programs in areas including multiple sclerosis and oncology, although its pipeline has changed over time as programs have advanced or been discontinued.

Founded in 2012 and headquartered in Thousand Oaks, California, Atara has focused primarily on serving patients in the United States and international markets through regulatory submissions, partnerships and commercialization agreements. Pascal Touchon has served as the company’s president and chief executive officer. As with other biotechnology companies, Atara’s product portfolio and corporate structure may change as clinical, regulatory and commercial activities progress.